Navigation Links
YM BioSciences Announces Secondary Efficacy and Safety Findings in,Randomized Phase IIB Aerolef Trial

- Company Announces Lead Investigator for U.S. Trial -

MISSISSAUGA, ON, July 11, 2007 /PRNewswire-FirstCall/ - YM BioSciences Inc. , an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced results of secondary endpoint data from its 99 patient, randomized, placebo-controlled, multi-center Phase IIb trial (DLXLEF-AP4) with AeroLEF(TM). AeroLEF(TM) is a unique, inhaled-delivery composition of free and liposome-encapsulated fentanyl in development for the treatment of moderate to severe pain, including cancer pain. YM previously announced that this trial had successfully achieved its primary endpoint, the summed pain intensity difference/pain relief scores (SPRID4) during the 4 hours from the start of the initial dose of study medication (p=0.0194).

Additional Secondary Efficacy and Safety Findings

The treatment phase of the study began in the post-anesthetic care unit (PACU) after completion of surgery when patients reported a pain intensity score (PI) of at least 2 (moderate pain) on a 4-point verbal rating scale (0 (none) to 3 (severe pain)). The clinical trial study period was up to 12 hours and patients were allowed to self-administer AeroLEF(TM) to treat up to two additional pain episodes during the study period. For each pain episode, patients were instructed to continue the self-administration of drug until achievement of one of the following endpoints: achievement of effective analgesia, completion of full dose, or onset of dose-limiting side effects. Patients were allowed rescue medication at any time following initiation of study treatment.

For the first dose administered in the PACU, the percentage of patients reporting a pain intensity (PI) score of less than or equal to 1 (mild pain or no pain) at the end of the dosing period with AeroLEF(TM) was 59%, a statistically significant difference from placebo (27%)
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
2. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
3. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
4. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
5. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
6. ImmuneRegen BioSciences Announces Promising Data on Homspera Suggesting Potential as a Co-Therapeutic Agent
7. Study in Cell by Magen BioSciences Co-Founder David E. Fisher Identifies New Roles in Skin Cancer Prevention for Key Tumor Suppressor Protein
8. IR BioSciences Announces Data Demonstrating Radilex Stimulation of Stem Cells Results in Hematopoietic Recovery Following Lethal Irradiation
9. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
10. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis

Post Your Comments:
(Date:11/6/2009)...N, Mass., Nov. 6 DUSA Ph...ermatology company that is developing and marketin...ther products focused on patients with common skin...nd Chief Executive Officer, will present a corpora...ummit 2009 on Tuesday, November 10, 2009 at 10:00 ...
(Date:11/6/2009)... Fla., Nov. 6 Roper Ind...it has signed a definitive agreement to acquire Ve...dical devices. The Verathon Board of Directors ha...ect to customary regulatory approvals and closing ...arties expect the closing to be completed in early...
(Date:11/6/2009)..., Mass., Nov. 6 Facet Solutions, I...e assets of Archus Orthopedics. The acquisition cr... offerings, intellectual property and clinical exp... a win for patients suffering from lumbar spinal s...CEO, Geoff Pardo. "This consolidation further str...
Breaking Medicine Technology:Roper Industries Announces Two Acquisitions to Enhance Growth in Medical and Toll & Traffic Businesses 2Roper Industries Announces Two Acquisitions to Enhance Growth in Medical and Toll & Traffic Businesses 3Facet Solutions Acquires Archus Orthopedics 2Mexico Premiere for Money Saving Pharma Leak Testing Equipment 12573 1Mexico Premiere for Money Saving Pharma Leak Testing Equipment 12573 2Mexico Premiere for Money Saving Pharma Leak Testing Equipment 12573 3Clearly Contacts Announces Another Quarter Of Growth In The Economic Downturn 48555 1Clearly Contacts Announces Another Quarter Of Growth In The Economic Downturn 48555 2Clearly Contacts Announces Another Quarter Of Growth In The Economic Downturn 48555 3Omega 3 EPA 3A Treatment for a Heart Condition 48552 1Omega 3 EPA 3A Treatment for a Heart Condition 48552 2Omega 3 EPA 3A Treatment for a Heart Condition 48552 3Omega 3 EPA 3A Treatment for a Heart Condition 48552 4Omega 3 EPA 3A Treatment for a Heart Condition 48552 5Omega 3 EPA 3A Treatment for a Heart Condition 48552 6
...t. 19 Immtech Pharmaceuticals,Inc. (Amex: IMM ) ...stration,(FDA) has granted Orphan Drug Designation...n Trypanosomiasis (HAT), also known as African,sle...mmtech with numerous,financial and regulatory bene...overnment grants for conducting clinical trials, w...
...Presented at the 47th Annual Interscience Conferen...motherapy, LOUISVILLE, Colo., Sept. 19 Replidyne...eclinical studies, its,antibacterial candidate REP...e intestinal toxins caused by Clostridium difficil... disease (CDAD), an,inflammatory condition caused ...
Other Medicine Technology:US FDA Grants Orphan Drug Status to Immtech's Pafuramidine for Treatment of African Sleeping Sickness 2US FDA Grants Orphan Drug Status to Immtech's Pafuramidine for Treatment of African Sleeping Sickness 3Replidyne's Investigational Antibacterial Agent REP3123 Prevents Toxin Production in Clostridium difficile 2Replidyne's Investigational Antibacterial Agent REP3123 Prevents Toxin Production in Clostridium difficile 3Replidyne's Investigational Antibacterial Agent REP3123 Prevents Toxin Production in Clostridium difficile 4
(Date:11/7/2009)...The Public Relations Society of America (PRSA) wil...e Gage Lofgren, senior vice president of Brand Str..., tonight at a ceremony at PRSA,s 2009 Internation...nto the PRSA College of Fellows is one of the prof...Herman, APR, SAGE, Fellow PRSA, and 2009 chair of ...
(Date:11/7/2009)...o stem a growing problem across the U.S. , ...f of students at four-year colleges do it regularl...ng -- downing five or more alcoholic drinks at a s...ohol as a drug," said Jenny Hwang, associate dean ...at Stony Brook University on Long Island, N.Y. In ...
(Date:11/7/2009)... In the current economic climate, many Americ...re only spending money on what that they consider ...rgeon David D. Kim believes that it’s very ...o receive treatment to improve their health, and h... to patients in this tough economy by offering rea...
(Date:11/7/2009)... A new foot spray from Greensations fights pa... peppers and caffeine. ThermaFeet targets foot pai...t also contains Black Walnut, Goldenseal, Vitamin ... Schenectady, NY (PRWEB) November 7, 2009 -- A ...ncreases circulation with the power of hot peppers...
(Date:11/6/2009)...cently a Narconon of Georgia graduate was featured...escription drug abuse. The special report focused ...ction . In the report Andrew shared his near dea...one to prevent prescription drug abuse. ,, "I woke...ed my eyes to my father on top of me giving me CPR...
Breaking Medicine News(10 mins):Health News:PRSA Inducts Head of Public Relations for Kaiser Permanente Into the College of Fellows for Contributions to the Profession and Lifetime Achievement 2Health News:PRSA Inducts Head of Public Relations for Kaiser Permanente Into the College of Fellows for Contributions to the Profession and Lifetime Achievement 3Health News:Binge Drinking Puts the Brain, and Life Itself, at Risk 2Health News:Binge Drinking Puts the Brain, and Life Itself, at Risk 3Health News:Dallas Bariatric Surgeon Offers Multiple Options for Patients Considering Weight Loss Surgery in a Rough Economy 2Health News:Dallas Bariatric Surgeon Offers Multiple Options for Patients Considering Weight Loss Surgery in a Rough Economy 3Health News:Hot Peppers and Caffeine Relieve Painful Feet, Toe Fungus and Foot Odor 2Health News:Narconon Drug Rehab of Georgia Graduate Featured on Local News 2
...Prominent New York personal injury lawyer reacts t... that cites major problems injured workers face wh...rk state. , New York, NY ...r than face another day of frustration and failure...
...s Benefit from Personalized Attention , , DENVER,...elbow specialist at Western Orthopaedics, speciali... everything from a 45-minute technique called shou...e American Academy of Orthopaedic Surgeons, there ...
...hing which preterm infants are at risk of developi...ain. A new study from the Sahlgrenska Academy, Uni...wing weekly weight development might replace the n.... Preterm infants are at increased risk of damage ...
... Children International,s Youth Health Corps ...ound the world at record rates! , , To view the ...wire.com/mnr/childreninternational/37664/ , , (P... completed training in order to teach their peers ...
...of the art Fujitsu PalmSecure(TM) Biometric Authen...ing, and patient information updating to revolutio...actices , , CHICAGO and SUNNYVALE, Calif., April ...Allscripts Patient Kiosk (TM), the next generat...
...nsulting and Siebel Systems involved with new inde...l 7 Univita Health, a new company aimed at promot...ependent aging, today announced the election of Ge...nd is joining us on our mission to help people liv...
Other Medicine News:Health News:Workers Comp Troubles Making You Sick? New York Personal Injury Lawyers Might Just Have the Cure 2Health News:Workers Comp Troubles Making You Sick? New York Personal Injury Lawyers Might Just Have the Cure 3Health News:Workers Comp Troubles Making You Sick? New York Personal Injury Lawyers Might Just Have the Cure 4Health News:Western Orthopaedics in Denver Blends Innovative Techniques to Provide a Spectrum of Shoulder Care 2Health News:Western Orthopaedics in Denver Blends Innovative Techniques to Provide a Spectrum of Shoulder Care 3Health News:New, simple method identifies preterm infants at risk of eye disease 2Health News:Photos: Report Shows Youth Health Educators Reach More Poor Teens with a Message of Living Healthy Lives! 2Health News:Allscripts Integrates Electronic Health Record With Innovative Patient Kiosk 2Health News:Allscripts Integrates Electronic Health Record With Innovative Patient Kiosk 3Health News:Allscripts Integrates Electronic Health Record With Innovative Patient Kiosk 4Health News:Allscripts Integrates Electronic Health Record With Innovative Patient Kiosk 5Health News:Allscripts Integrates Electronic Health Record With Innovative Patient Kiosk 6Health News:Allscripts Integrates Electronic Health Record With Innovative Patient Kiosk 7Health News:George T. Shaheen Joins Board of Directors at Univita Health 2
...is clinically proven to reduce the appearance of c...-gel formula combines Retinol, the purest form of ...orks deep within skin's surface to improve elastic... absorbing, it has a fresh, clean scent and leaves...
...been developed specifically to fight Cellulite in ... does this by stimulating and massaging the lymph ...ch then are removed naturally. Initially, we recom...each treatment. After noticing visible results, th...
Ritter 204 Manual Exam Table
DermMaster II Salt-A-Peel™ Microdermabrasion
Medicine Products: